-

76  articles.  
* There may be some overlapped articles listed due to the difference of format.

  1. Reda O, Monde K, Sugata K, Rahman A, Sakhor W, Rajib SA, Sithi SN, Tan BJY, Niimura K, Motozono C, Maeda K, Ono M, Takeuchi H, Satou Y: HIV-Tocky system to visualize proviral expression dynamics. Communications biology. 2024.03; 7 (1): 344. ( PubMed , DOI )

  2. Kei Taga, Hiroaki Takeuchi: Novel role of host protein SLC25A42 in the HIV-1 reactivation of latent HIV-1 provirus Microbiology and Immunology. 2024.01; 1-10. ( DOI )

  1. Tatsuya Iida, Jun Ando, Hajime Shinoda, Asami Makino, Mami Yoshimura, Kazue Murai, Makiko Mori, Hiroaki Takeuchi, Takeshi Noda, Hiroshi Nishimasu, Rikiya Watanabe: Compact wide-field femtoliter-chamber imaging system for high-speed and accurate digital bioanalysis. Lab on a Chip. 2023.02; ( PubMed , DOI )

  2. Takatsuki Y., Takahashi Y., Nakajima J., Iwasaki Y., Nagano K., Tani-Sassa C., Yuasa S., Kanehira S., Sonobe K., Nukui Y., Takeuchi H., Tanimoto K., Tanaka Y., Kimura A., Ichimura N., and Tohda S.: Viral load of SARS-CoV-2 Omicron BA.5 is lower than that of BA.2 despite higher infectivity of BA.5. Immunity, Inflammation and Disease. 2023.02; 11 e783. ( DOI )

  3. Kitamura H., Sukegawa S., Matsuda K., Tanimoto K., Kobayakawa T., Takahashi K., Tamamura H., Tsuchiya K., Gatanaga H., Maeda K., and Takeuchi H.: 4-phenylquinoline-8-amine induces HIV-1 reactivation and apoptosis in latently HIV-1 infected cells. Biochemical and Biophysical Research Communications. 2023.01; 641 139-147. ( PubMed , DOI )

  1. Sayaka Sukegawa and Hiroaki Takeuchi: Toward the unveiling of HIV-1 dynamics: Involvement of monocytes/macrophages in HIV-1 infection Frontiers in Virology. 2022.07; ( DOI )

  2. Nishiyama Takara, Takada Toru, Takeuchi Hiroaki, Iwami Shingo: Maternal embryonic leucine zipper kinase (MELK) optimally regulates the HIV-1 uncoating process JOURNAL OF THEORETICAL BIOLOGY. 2022.07; 545 111152. ( PubMed , DOI )

  3. Yuasa S, Nakajima J, Takatsuki Y, Takahashi Y, Tani-Sassa C, Iwasaki Y, Nagano K, Sonobe K, Yoshimoto T, Nukui Y, Takeuchi H, Tanimoto K, Tanaka Y, Kimura A, Ichimura N, Tohda S.: Viral load of SARS-CoV-2 Omicron is not high despite its high infectivity Journal of Medical Virology. 2022.07; 94 (11): 5543-5546. ( PubMed , DOI )

  4. Shinoda Hajime, Iida Tatsuya, Makino Asami, Yoshimura Mami, Ishikawa Junichiro, Ando Jun, Murai Kazue, Sugiyama Katsumi, Muramoto Yukiko, Nakano Masahiro, Kiga Kotaro, Cui Longzhu, Nureki Osamu, Takeuchi Hiroaki, Noda Takeshi, Nishimasu Hiroshi, Watanabe Rikiya: Automated amplification-free digital RNA detection platform for rapid and sensitive SARS-CoV-2 diagnosis COMMUNICATIONS BIOLOGY. 2022.05; 5 (1): 473. ( PubMed , DOI )

  5. Horiguchi Yukichi, Naono Norihiko, Sakamoto Osamu, Takeuchi Hiroaki, Yamaoka Shoji, Miyahara Yuji: Methodology to Detect Biological Particles Using a Biosensing Surface Integrated in Resistive Pulse Sensing ACS APPLIED MATERIALS & INTERFACES. 2022.04; 14 (17): 20168-20178. ( PubMed , DOI )

  6. Tani-Sassa C, Iwasaki Y, Ichimura N, Nagano K, Takatsuki Y, Yuasa S, Takahashi Y, Nakajima J, Sonobe K, Nukui Y, Takeuchi H, Tanimoto K, Tanaka Y, Kimura A, Tohda S.: Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha, or R.1 variants in Tokyo Journal of Medical Virology. 2022.04; 94 (4): 1707-1710. ( PubMed , DOI )

  7. Arakawa M, Tabata K, Ishida K, Kobayashi M, Arai A, Ishikawa T, Suzuki R, Takeuchi H, Tripathi LP, Mizuguchi K, Morita E: Flavivirus recruits the valosin-containing protein (VCP)/NPL4 complex to induce stress granule disassembly for efficient viral genome replication. The Journal of biological chemistry. 2022.01; 298 (3): 101597. ( PubMed , DOI )

  1. Reda O., Monde K., Sugata K., Rahman A., Sakhor W., Tan B. J., Matsuo M., Takeuchi H., Ono M., Satou Y.: A new in-vitro model to monitor HIV-1 proviral transcription by timer-fluorescence protein HIV MEDICINE. 2021.10; 22 54-55.

  2. Deletsu Selase D., Kitamura Haruki, Ishida Takaomi, Gohda Jin, Yamaoka Shoji, Takeuchi Hiroaki: Identification and characterization of Stathmin 1 as a host factor involved in HIV-1 latency BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2021.08; 567 106-111. ( PubMed , DOI )

  3. Nagano K, Tani-Sassa C, Iwasaki Y, Takatsuki Y, Yuasa S, Takahashi Y, Nakajima J, Sonobe K, Ichimura N, Nukui Y, Takeuchi H, Tanimoto K, Tanaka Y, Kimura A, Tohda S: SARS-CoV-2 R.1 lineage variants prevailed in Tokyo in March 2021. Journal of medical virology. 2021.07; ( PubMed , DOI )

  4. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, Kamiya M, Yamamoto A, Ando T, Shimada S, Shirai T, Okamoto T, Tateishi T, Endo A, Aiboshi J, Nosaka N, Yamanouchi H, Ugawa T, Nagaoka E, Oi K, Tao S, Maejima Y, Tanaka Y, Tanimoto K, Takeuchi H, Tohda S, Hirakawa A, Sasano T, Arai H, Otomo Y, Miyazaki Y, Yasuda S: Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. Frontiers in cardiovascular medicine. 2021; 8 767074. ( PubMed , DOI )

  1. Lotfi S, Nasser H, Noyori O, Hiyoshi M, Takeuchi H, Koyanagi Y, Suzu S: M-Sec facilitates intercellular transmission of HIV-1 through multiple mechanisms. Retrovirology. 2020.07; 17 (1): 20. ( PubMed , DOI )

  2. Weitong Yao, Takeshi Yoshida, Saki Hashimoto, Hiroaki Takeuchi, Klaus Strebel, Shoji Yamaoka: Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs. J. Virol.. 2020.01; 94 (2): ( PubMed , DOI )

  1. H. Takeuchi, T. Ishida, Y. Satou, J. Gohda, H. Kitamura, S. Gan, K. Takahashi, S. Yamaoka: Genome-wide RNAi screen identifies MAPK-RPK required for HIV-1 proviral silencing in non-T cell reservoir cell-line model Journal of Virus Eradication. 2019.12; 5 (Supplement 3): 5. ( DOI )

  2. Iwase CS., Miyazato P., Katsuya H., Islam S., Yang TJS., Ito J., Matsuo M., Takeuchi H., Ishida T., Matsuda K., Maeda K., and Satou Y.: HIV-1 DNA-capture-seq is a useful tool for the comprehensive characterization of HIV-1 provirus. Scientific Reports. 2019.08; 9 (1): 12326. ( DOI )

  3. Kenji Maeda, Debananda Das, Takuya Kobayakawa, Hirokazu Tamamura, Hiroaki Takeuchi: Discovery and Development of anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. Current topics in medicinal chemistry. 2019.07; 19 (18): 1621-1649. ( PubMed , DOI )

  4. Maeda K., Das D., Kobayakawa T., Tamamura H., and Takeuchi H: Discovery and Development of anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. Current Topics in Medicinal Chemistry. 2019.07; 19 1-29. ( DOI )

  5. Aziati ID, Yoshida T, Hamano A, Maeda K, Takeuchi H, Yamaoka S: PATZ1 is required for efficient HIV-1 infection. Biochemical and biophysical research communications. 2019.06; 514 (2): 538-544. ( PubMed , DOI )

  1. Yoshida Takeshi, Kawamura Saki, Yamaguchi Haruka, Takeuchi Hiroaki, Yamaoka Shoji: Identification of a host factor supporting HIV-1 entry(和訳中) 日本エイズ学会誌. 2018.11; 20 (4): 537. ( ichushi )

  2. Suzuki N., Yoshida T., Takeuchi H., Sakuma R., Sukegawa S., and Yamaoka S.: Robust enhancement of lentivirus production by promoter activation. Scientific Reports. 2018.09;

  3. Yukichi Horiguchi, Tatsuro Goda, Akira Matsumoto, Hiroaki Takeuchi, Shoji Yamaoka, Yuji Miyahara: Gold Nanoparticles with Ligand/Zwitterion Hybrid Layer for Individual Counting of Influenza A H1N1 Subtype Using Resistive Pulse Sensing. Langmuir. 2018.08; 35 (5): 1798-1806. ( PubMed , DOI )

  4. Jerry Kwame Ndzinu, Hiroaki Takeuchi, Hideki Saito, Takeshi Yoshida, Shoji Yamaoka: eIF4A2 is a host factor required for efficient HIV-1 replication. Microbes Infect.. 2018.05; 20 (6): 346-352. ( PubMed , DOI )

  5. Jin Gohda, Kazuo Suzuki, Kai Liu, Xialin Xie, Hiroaki Takeuchi, Jun-Ichiro Inoue, Yasushi Kawaguchi, Takaomi Ishida: BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1. Sci Rep. 2018.02; 8 (1): 3521. ( PubMed , DOI )

  6. Osako M., Itsumi M., Yamaguchi H., Takeuchi H., and Yamaoka S.: A20 restores phorbol ester-induced differentiation of THP-1 cells in the absence of nuclear factor-κB activation. Journal of Cellular Biochemistry. 2018.02; 119 (2): 1475-1487. ( PubMed , DOI )

  7. Hai W., Goda T., Takeuchi H., Yamaoka S., Horiguchi Y., Matsumoto A., and Miyahara Y: Human Influenza Virus Detection Using Sialyllactose-Functionalized Organic Electrochemical Transistors. Sensors & Actuators B-Chemical. 2018.01;

  1. Takeshi Yoshida, Akiko Hamano, Asuka Ueda, Hiroaki Takeuchi, Shoji Yamaoka: Human SMOOTHENED inhibits human immunodeficiency virus type 1 infection. Biochem. Biophys. Res. Commun.. 2017.11; 493 (1): 132-138. ( PubMed , DOI )

  2. Hideki Saito, Hiroaki Takeuchi, Takao Masuda, Takeshi Noda, Shoji Yamaoka: N-terminally truncated POM121C inhibits HIV-1 replication. PLoS ONE. 2017.09; 12 (9): e0182434. ( PubMed , DOI )

  3. Hiroaki Takeuchi, Hideki Saito, Takeshi Noda, Tadashi Miyamoto, Tomokazu Yoshinaga, Kazutaka Terahara, Hiroshi Ishii, Yasuko Tsunetsugu-Yokota, Shoji Yamaoka: Phosphorylation of the HIV-1 capsid by MELK triggers uncoating to promote viral cDNA synthesis. PLoS Pathog. 2017.07; 13 (7): e1006441. ( PubMed , DOI )

  4. Yukichi Horiguchi, Tatsuro Goda, Akira Matsumoto, Hiroaki Takeuchi, Shoji Yamaoka, Yuji Miyahara: Direct and label-free influenza virus detection based on multisite binding to sialic acid receptors. Biosens Bioelectron. 2017.06; 92 234-240. ( PubMed , DOI )

  5. Wenfeng H., Goda T., Takeuchi H., Yamaoka S., Horiguchi Y., Akira M., and Miyahara Y.: Specific Recognition of Human Influenza Virus with PEDOT Bearing Sialic Acid-Terminated Trisaccharides. ACS Applied Materials & Interfaces. 2017.04; 9 (16): 14162-14170. ( PubMed , DOI )

  1. Sukegawa S., Sakuma R., Ohmine S., Takeuchi H., Ikeda Y and Yamaoka S.: Suppressor of Cytokine Signaling 1 Counteracts Rhesus Macaque TRIM5a-Induced Inhibition of Human Immunodeficiency Virus Type-1 Production. PLoS ONE. 2014.09; 9 (10): e109640. ( PubMed )

  1. Sugiyama R., Abe M., Nishitsuji H., Murakami Y., Takeuchi H., and Takaku H.: Induction of heat-shock protein 70 by prostaglandin A1 inhibits HIV-1 Vif-mediated degradation of APOBEC3G. Antiviral Research. 2013.09; 99 (3): 307-311. ( PubMed )

  2. Takanori Hori, Hiroaki Takeuchi, Hideki Saito, Ryuta Sakuma, Yoshio Inagaki, Shoji Yamaoka: A carboxy-terminally truncated human CPSF6 lacking residues encoded by exon 6 inhibits HIV-1 cDNA synthesis and promotes capsid disassembly. J. Virol.. 2013.07; 87 (13): 7726-7736. ( PubMed , DOI )

  1. Ryuta Sakuma, Hiroaki Takeuchi: SIV replication in human cells. Front Microbiol. 2012.04; 3 162. ( PubMed , DOI )

  2. Hiroaki Takeuchi, Hiroshi Ishii, Tetsuya Kuwano, Natsuko Inagaki, Hirofumi Akari, Tetsuro Matano: Host cell species-specific effect of cyclosporine A on simian immunodeficiency virus replication. Retrovirology. 2012.01; 9 3. ( PubMed , DOI )

  1. Sugiyama R., Nishitsuji H., Furukawa A., Katahira M., Habu Y., Takeuchi H., Ryo A., and Takaku H.: Heat shock protein 70 inhibits HIV-1 Vif-mediated ubiquitination and degradation of APOBEC3G. Journal of Biological Chemistry. 2011; 286 (12): 10051-10057.

  2. Ohmine S., Sakuma R., Sakuma T., Thatava T., Takeuchi H., and Ikeda Y.: The antiviral spectra of TRIM5α orthologues and human TRIM family proteins against lentiviral production. PLoS ONE. 2011; 6 (1): e16121.

  1. Hiroaki Takeuchi: Contribution of Cyclophilin A to determination of simian immunodeficiency virus tropism: a progress update. Vaccine. 2010.05; 28 Suppl 2 B51-B54. ( PubMed , DOI )

  2. Iwamoto N., Tsukamoto T., Kawada M., Takeda A., Yamamoto H., Takeuchi H., and Matano T.: Broadening of CD8+ cell responses in vaccine-based simian immunodeficiency virus controllers. AIDS. 2010; 24 (18): 2777-2787.

  3. Inagaki N., Takeuchi H*., Yokoyama M., Sato H., Ryo A., Yamamoto H., Kawada M., and Matano T.: A structural constraint for functional interaction between N-terminal and C-terminal domains in simian immunodeficiency virus capsid proteins. Retrovirology. 2010; (7): 90.

  1. Hiroaki Takeuchi, Tetsuro Matano: Host factors involved in resistance to retroviral infection. Microbiol. Immunol.. 2008.06; 52 (6): 318-325. ( PubMed , DOI )

  2. Kawada M., Tsukamoto T., Yamamoto H., Iwamoto N., Kurihara K., Takeda A., Moriya C., Takeuchi H., Akari H., and Matano T.: Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. Journal of Virology. 2008; 82 (20): 10199-10206.

  3. Goila-Gaur R., Khan MA., Miyagi E., Kao S., Opi S., Takeuchi H., and Strebel K.: HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology. 2008; 372 (1): 136-146.

  1. Hiroaki Takeuchi, Alicia Buckler-White, Ritu Goila-Gaur, Eri Miyagi, Mohammad A Khan, Sandrine Opi, Sandra Kao, Elena Sokolskaja, Thomas Pertel, Jeremy Luban, Klaus Strebel: Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J. Virol.. 2007.08; 81 (15): 8080-8090. ( PubMed , DOI )

  2. Kao S., Goila-Gaur R., Miyagi E., Kahn MA., Opi S., Takeuchi H., and Strebel K. : Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology. 2007; 369 (2): 329-339.

  3. Miyagi E., Opi S., Takeuchi H., Khan MA., Goila-Gaur R., Kao S., and Strebel K. : Enzymatically Active APOBEC3G Is required for Efficient Inhibition of HIV-1. Journal of Virology. 2007; 81 (24): 13346-13353.

  4. Opi S., Kao S., Goila-Gaur R., Khan MA., Miyagi E., Takeuchi H., and Strebel K. : Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. Journal of Virology. 2007; 81 (15): 8236-8246.

  5. Khan MA., Goila-Gaur R., Opi S., Miyagi E., Takeuchi H., Kao S., and Strebel K. : Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology. 2007; 4 (1): 48.

  1. Iwatani Y., Takeuchi H*., Strebel K., and Levin JG.: Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. Journal of Virology. 2006; 80 (12): 5992-6002.

  2. Eda Y., Murakami T., Ami Y., Nakasone T., Takizawa M., Someya K., Kaizu M., Izumi Y., Yoshino N., Matsushita S., Higuchi H., Matsui H., Shinohara K., Takeuchi H., Koyanagi Y., Yamamoto N., and Honda M.: Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection. Journal of Virology. 2006; 80 (11): 5563-5570.

  3. Opi S., Takeuchi H*., Kao S., Khan MA., Miyagi E., Goila-Gaur R., Iwatani Y., Levin LG., and Strebel K.: Monomeric APOBEC3G is catalytically active and has antiviral activity. Journal of Virology. 2006; 80 (10): 4673-4682.

  1. Hiroaki Takeuchi, Sandra Kao, Eri Miyagi, Mohammad A Khan, Alicia Buckler-White, Ron Plishka, Klaus Strebel: Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G. J. Biol. Chem.. 2005.01; 280 (1): 375-382. ( PubMed , DOI )

  2. Khan MA., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson CL., Parslow TG., Ly H., and Strebel K. : Viral RNA is required for the Association of APOBEC3G with HIV-1 Nucleoprotein Complexes. Journal of Virology. 2005; 79 (9): 5870-5874.

  3. Habu Y., Nagawa T., Matsumoto N., Takeuchi H., Miyano-Kurosaki N., and Takaku H.: Suppression of human immunodeficiency virus type 1 (HIV-1) replication by an HIV-1-dependent double locked vector with the Cre/loxP system. Nucleosides Nucleotides Nucleic Acids. 2005; 24 (10-12): 1907-1917.

  1. Miyano-Kurosaki N., Barnor JS., Takeuchi H., Owada T., Nakashima H., Yamamoto N., Matsuzaki T., Shimada F., and Takaku H.: In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes. Antiviral Chemistry and Chemotherapy. 2004; 15 (2): 93-100.

  2. Kao S., Miyagi E., Khan MA., Takeuchi H., Opi S., Goila-Gaur R., and Strebel K.: Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology. 2004; 1 (1): 27.

  1. Kuwasaki T., Hatta M., Takeuchi H., and Takaku H.: Inhibition of human immunodeficiency virus 1 replication in vitro by a self-stabilized oligonucleotide with 2'-O-methyl-guanosine-uridine quadruplex motifs. Journal of Antimicrobial Chemotherapy. 2003; 51 (4): 813-819.

  1. Hiroaki Takeuchi, Youichi Suzuki, Masashi Tatsumi, Hiroo Hoshino, Eric S Daar, Yoshio Koyanagi: Isolation and characterization of an infectious HIV type 1 molecular clone from a patient with primary infection. AIDS Res. Hum. Retroviruses. 2002.10; 18 (15): 1127-1133. ( PubMed , DOI )

  2. Suzuki J., Miyano-Kurosaki N., Kuwasaki T., Takeuchi H., Kawai G., and Takaku H.: Inhibition of human immunodeficiency virus type 1 activity in vitro by a new self-stabilized oligonucleotide with guanosine-thymidine quadruplex motifs. Journal of Virology. 2002; 76 3015-3022.

  3. Inagawa T., Nakashima H., Karwowski B., Guga P., Stec WJ., Takeuchi H., and Takaku H.: Inhibition of Human Immunodeficiency Virus Type-1 replication by P-stereodefined oligo (nucleoside phosphorothioate)s in a long-term infection model. FEBS Letter . 2002; 528 (1-3): 48-52.

  4. Nagawa T., Habu Y., Matsumoto N., Takeuchi H., Miyano-Kurosaki N., and Takaku H.: Development of HIV-1 dependent gene expression vector with the Cre/loxP (ON) system. Nucleic Acids Resarch. 2002; Supplement 2 295-296.

  5. Habu Y., Miyano-Kurosaki N., Nagawa T., Matsumoto N., Takeuchi H*., and Takaku H.: Inhibition of HIV-1 replication by an HIV-1 dependent ribozyme expression vector with the Cre/loxP (ON/OFF) system. Antiviral Chemistry and Chemotherapy. 2002; 13 (5): 273-281.

  6. Yukita M., Kitano M., Miyano-Kurosaki N., Takeuchi H., Nashimoto M., and Takaku H.: RNA cleavage by a mammalian tRNA 3' processing endoribonuclease (3'tRNase) reduces HIV-1 expression. Nucleic Acids Resarch. 2002; Supplement 2 297-298.

  1. Habu Y., Miyano-Kurosaki N., Takeuchi H., Matsumoto N., Tamura Y., and Takaku H.: Inhibition of HIV-1 replication by the Cre-loxP hammerhead ribozyme. Nucleosides Nucleotides Nucleic Acids. 2001; 20 (4-7): 723-726.

  2. Kitano M., Barnor JS., Miyano-Kurosaki N., Endo Y., Yukita M., Takeuchi H., Tamura Y., Takai K., Nashimoto M., and Takaku H.: Effective suppression of HIV-1 gene expression by a mammalian tRNA 3' processing endoribonuclease and external guide sequence oligozymes. Nucleosides Nucleotides Nucleic Acids. 2001; 20 (4-7): 719-722.

  1. Habu Y., Takeuchi H*., Tamura Y., Miyano-Kurosaki N., Takai K., and Takaku H.: Development of an HIV-1-dependent expression vector with the Cre/loxP system. Nucleic Acids Symposium Series. 1999; (42): 295-296.

  2. Suzuki J., Miyano-Kurosaki N., Takeuchi H., Tamura Y., Kawai G., Takai K., Tanaka Y., Tanaka R., Yamamoto N., and Takaku H.: Phosphorothioate G3T4G3 motifs inhibit the early stage of HIV-1 infection. Nucleic Acids Symposium Series. 1999; (42): 227-228.

  3. Kitano M., Miyano-Kurosaki N., Endo Y., Yukita M., Takeuchi H., Tamura Y., Takai K., Nashimoto M., and Takaku H. : Effective suppression of HIV-1 gene expression by a mammalian tRNA 3' processing endoribonuclease and external guide sequence oligozymes. Nucleic Acids Symposium Series. 1999; (42): 207-208.

  4. Hosoya T., Takeuchi H*., Kanesaka Y., Yamakawa H., Miyano-Kurosaki N., Takai K., Yamamoto N., and Takaku H.: Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Letters . 1999; 19 (461 (3)): 136-140.

  1. Tsukahara S., Suzuki J., Goto Y., Inagawa T., Takeuchi H., Takai K., Koyanagi Y., Yamamoto N., and Takaku H.: Inhibition of gene expression by oligonucleotides forming triple-helices with the polypurine tract of HIV-1. Nucleic Acids Symposium Series. 1996; (35): 181-182.

  1. Investigation of newly identified host proteins regulating HIV-1 infection The Journal of AIDS Research. 2018.06; 20 117-123.

To the head of this page.▲